A Multinational, Multicenter, Randomized, Comparative, Open-label, Phase 3 Study to Assess the Immunogenicity and Safety of DTaP-IPV (Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus) Vaccine Administered to Healthy Infants

Trial Profile

A Multinational, Multicenter, Randomized, Comparative, Open-label, Phase 3 Study to Assess the Immunogenicity and Safety of DTaP-IPV (Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus) Vaccine Administered to Healthy Infants

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs DTaP poliovirus vaccine (Primary) ; DTaP vaccine; Poliovirus vaccine
  • Indications Diphtheria; Pertussis; Poliomyelitis; Tetanus
  • Focus Therapeutic Use
  • Acronyms VENUS
  • Sponsors Boryung Pharmaceutical
  • Most Recent Events

    • 03 Feb 2017 Planned End Date changed from 1 Sep 2017 to 1 Apr 2018.
    • 11 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top